Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 3, 2020MoleculesOpen Access

Structure-based drug design targeting the RNA-dependent RNA polymerase has yielded successful antivirals for HCV and SARS-CoV-2, but progress in Flaviviruses is hampered by a lack of structural data.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

RdRp is an essential enzyme for viral replication and an optimal target for antiviral drug development, but the lack of structural details on catalytically-competent or ligand-bound RdRp can hamper structure-based drug design.

Design

Review

Key result

Structure-based drug design targeting the RNA-dependent RNA polymerase has yielded successful antivirals for HCV and SARS-CoV-2, but progress in Flaviviruses is hampered by a lack of structural data.

Authors

FPFrancesca PicarazziIVIlaria VicentiFSFrancesco Saladini

Discussion

Loading...

Member takes

Overview

RdRp targeting may guide antivirals in virus-related cardiac injury; leaves open specific cardiovascular applications.

Structured PICO

P
Population
RNA-dependent RNA polymerase (RdRp) of emerging RNA viruses such as Coronaviruses, Flaviviruses, and Hepatitis C virus (HCV)
I
Intervention
Structure-based drug design and inhibition strategies

Structure-based drug design targeting RdRp has been successful for HCV and SARS-CoV-2, but is hindered in Flaviviruses due to a lack of detailed structural information.

Limitations

  • Lack of structural details on catalytically-competent or ligand-bound RdRp strongly hampers the application of structure-based drug design for Flaviviruses.

Cite This Study

Picarazzi et al. (2020) conducted a review in Emerging RNA viruses (Coronaviruses, Flaviviruses, HCV). Structure-based drug design targeting RdRp was evaluated. Structure-based drug design targeting the RNA-dependent RNA polymerase has yielded successful antivirals for HCV and SARS-CoV-2, but progress in Flaviviruses is hampered by a lack of structural data.

synapsesocial.com/papers/6a6aeadd57a2ff847acb215ehttps://doi.org/10.3390/molecules25235695
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clustal W and Clustal X version 2.02007 · 29,311 citations
  2. 2Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor2009 · 120 citations
  3. 3The Genome Sequence of the SARS-Associated Coronavirus2003 · 2,089 citations
  4. 4Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin2013 · 277 citations
  5. 5RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution2018 · 431 citations